A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
about
Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRIPosterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.
P2860
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase I trial and PK study o ...... refractory primary CNS tumors.
@ast
A phase I trial and PK study o ...... refractory primary CNS tumors.
@en
type
label
A phase I trial and PK study o ...... refractory primary CNS tumors.
@ast
A phase I trial and PK study o ...... refractory primary CNS tumors.
@en
prefLabel
A phase I trial and PK study o ...... refractory primary CNS tumors.
@ast
A phase I trial and PK study o ...... refractory primary CNS tumors.
@en
P2093
P2860
P1476
A phase I trial and PK study o ...... refractory primary CNS tumors.
@en
P2093
Anu Banerjee
Arzu Onar-Thomas
Clinton F Stewart
David C Turner
Frederic Fahey
James M Boyett
Mark W Kieran
Marsha Moses
Regina Jakacki
P2860
P2888
P304
P356
10.1007/S00381-015-2812-5
P577
2015-07-19T00:00:00Z